ArticleToxins2022
Early Adverse Reactions to Snake Antivenom: Poison Center Data Analysis.
Article in Toxins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 20 citations in OpenAlex.
- Estimating the distributional impact of improving access to snake antivenom in urban and rural Lao People's Democratic Republic: An extended cost-effectiveness analysis.PLoS neglected tropical diseases · 2026Article
- A Paradigm Shift in Snakebite Envenoming Therapy: From Conventional Antivenoms to Rationally Designed, Broadly Neutralizing Combination Therapies.ACS pharmacology & translational science · 2026Review
- Cyanidin-3-O-glucoside (C3G): A natural small-molecule compound for alleviating envenomation symptoms Induced by Bungarus multicinctus.PLoS neglected tropical diseases · 2026Article
- Article
- Association between the 20-minute whole blood clotting test and fibrinogen concentrations in green pit viper envenomations in Bangkok.PLoS neglected tropical diseases · 2026Article
- Outcomes Associated With the Timing of Antivenom Administration in Bothrops and Crotalus Snakebite Envenomations.Revista da Sociedade Brasileira de Medicina Tropical · 2026Article
- Retrospective analysis of clinical and epidemiological characteristics of Chinese cobra bites in a South China emergency department.Scientific reports · 2025Article
- Review
- Physiological responses of the monocled cobra (The journal of venomous animals and toxins including tropical diseases · 2025Article
- The SnaFab versus the Razi antivenom for treatment of snakebite envenomation: A randomized, double-blind (investigator and victims), active controlled, non-inferiority clinical trial.PLOS global public health · 2025Article
- Article
- Neutralizing Nanobodies against Venoms fromToxins · 2024Article
- A Nationwide Study on the Risks of Complications and Healthcare Costs of Snakebite Envenomation in Taiwan.The American journal of tropical medicine and hygiene · 2024Article
- A Guide to the Clinical Management ofToxins · 2024Review
- Urgent administration of antivenom following proven krait bites in Southeast Asia irrespective of neurotoxic symptoms.PLoS neglected tropical diseases · 2024Article
- Review
- The Chinese guideline for management of snakebites.World journal of emergency medicine · 2024Article
- A Retrospective Cohort Study of Cobra Envenomation: Clinical Characteristics, Treatments, and Outcomes.Toxins · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antivenom is an essential treatment for snake envenomation; however, early adverse reactions (EARs) are major limitations to its use. We performed a retrospective cross-sectional study using Ramathibodi Poison Center data (January 2016 to December 2017) to clarify the incidence and severity of EARs following different F(ab’)2 antivenoms. Among 1006 envenomed patients, 684 (68%) received antivenom therapy with a total of 1157 doses, mostly green pit viper antivenom. The overall EAR incidence and rate were 22. 5% (154/684) and 15% (173/1157), respectively. The EAR rate following each type of antivenom was >10%, except for Russell’s viper antivenom (2.9%); the severe reaction rate was 2.6% (30/1157). Malayan pit viper bites caused a high incidence of EARs (37.8%) and the highest EAR rate (22.3%). Fifty-two cases developed anaphylaxis. All EARs occurred within 2 h after treatment initiation. No deaths were attributed to EARs. The duration of administration was significantly different between doses of antivenom that induced EARs and those that did not. In conclusion, all types and every dose of antivenom should be infused for 30−60 min. Preparation of resuscitation equipment and continuous clinical observation are crucial for at least 2 h after administration, and prompt treatment should be provided when EARs occur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.